2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2016

9:00AM-11:00AM: Abstract Number: 780

Belimumab Use in African-American Patients in an U.S. Academic Medical Center

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 12

Benefit of Early Therapy with Methotrexate and Prednisone in Patients with Early Rheumatoid Arthritis and Undifferentiated Early Arthritis (CONAART)

Epidemiology and Public Health - Poster I

9:00AM-11:00AM: Abstract Number: 774

BIIB059, an Anti-BDCA2 Monoclonal Antibody, Demonstrates Acceptable Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamic (PD) Effects in a Phase 1 Study with Single Ascending Doses (SAD) in Healthy Volunteers

Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster I: Clinical Trial Design and Current Therapies

9:00AM-11:00AM: Abstract Number: 331

Biologic Disease-Modifying Anti-Rheumatic Drug Use and the Risk of Non-Vertebral Osteoporotic Fractures in Japanese Patients with Rheumatoid Arthritis: Results from the IORRA Cohort Study

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 631

Biologic Free Remission Rate with Etanercept in Rheumatoid Arthritis: A Potential Role of Gender

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 637

Biologic Initiation Patterns Among Rheumatoid Arthritis Patients in Moderate or High Disease Activity While Using Conventional Disease Modifying Anti-Rheumatic Drugs

Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster I

9:00AM-11:00AM: Abstract Number: 799

Biomarker Identification & Molecular Sub-Classification in Systemic Sclerosis for Precision Medicine Using RNA-Seq

Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Pathogenesis, Animal Models and Genetics - Poster I

9:00AM-11:00AM: Abstract Number: 348

Bisphosphonates-Related Atypical Femur Fractures: 8 Years’ Experience in a Single Center

Osteoporosis and Metabolic Bone Disease – Clinical Aspects and Pathogenesis - Poster

9:00AM-11:00AM: Abstract Number: 548

Body Mass Index Is Positively Correlated with Diverse Disease Activity Measures in Longstanding Rheumatoid Arthritis

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 167

Bone Mineral Density Loss in Clinically Suspect Arthralgia Is Associated with Subclinical Inflammation and Progression to Clinical Arthritis

Imaging of Rheumatic Diseases - Poster I: Ultrasound and Emerging Technologies

9:00AM-11:00AM: Abstract Number: 546

Boolean-Based Remission in Rheumatoid Arthritis Using Physician Versus Patient Global Assessment: Differences in Ultrasonographic Disease Activities, Sustainabilities, and Relapse Rates

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 510

C-Reactive Protein and Disease Activity in Rheumatoid Arthritis: Impact of Obesity and Adiposity

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

9:00AM-11:00AM: Abstract Number: 128

Call to Action: Cardiovascular Comorbidities in Medicare Rheumatology Beneficiaries

Healthcare Disparities in Rheumatology - Poster I

9:00AM-11:00AM: Abstract Number: 381

Calprotectin As a Multipotent Biomarker in Juvenile Idiopathic Arthritis

Pediatric Rheumatology – Clinical and Therapeutic Aspects - Poster I: Juvenile Idiopathic Arthritis, Uveitis

9:00AM-11:00AM: Abstract Number: 492

Calprotectin Levels Correlate with Inflammation in Early Rheumatoid Arthritis before Disease-Modifying Antirheumatic Drug Treatment and after 12 Months of Treatment

Rheumatoid Arthritis – Clinical Aspects - Poster I: Clinical Characteristics/Presentation/Prognosis

«Previous Page
1
…
7
8
9
10
11
…
70
Next Page»

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].